 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7092 News |  |
| «12...2324252627282930313233...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
Preclinical, Journal: Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration. (Pubmed Central) - May 26, 2021
The preventive and therapeutic in vivo efficacy of Ac-RLYE via following intravitreal administration was determined to be either similar or superior to that of ranibizumab and aflibercept...Our results suggested that Ac-RLYE has a great potential for an alternative therapeutics for neovascular (wet) AMD. Since the amino acids in human VEGFR-2 targeted by Ac-RLYE are conserved among the animals employed in this study, the therapeutic efficacies of Ac-RLYE evaluated in those animals are predicted to be observed in human patients suffering from retinal degenerative diseases.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, HEOR: Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective. (Pubmed Central) - May 25, 2021
Since the amino acids in human VEGFR-2 targeted by Ac-RLYE are conserved among the animals employed in this study, the therapeutic efficacies of Ac-RLYE evaluated in those animals are predicted to be observed in human patients suffering from retinal degenerative diseases. The current Markov model demonstrated that ranibizumab may be cost-effective compared with laser photocoagulation to treat BRVO and cost-effective compared to observation-only care to treat CRVO in China from the societal perspective.
- ||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal, Adverse events: Drug-related adverse effects of antivascular endothelial growth factor agents. (Pubmed Central) - May 22, 2021
The current Markov model demonstrated that ranibizumab may be cost-effective compared with laser photocoagulation to treat BRVO and cost-effective compared to observation-only care to treat CRVO in China from the societal perspective. Newer anti-VEGF agents pose a significant risk of adverse events not seen with routine anti-VEGF agents.
- | Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Age, Initial Central Retinal Thickness, and OCT Biomarkers Have an Influence on the Outcome of Diabetic Macular Edema Treated With Ranibizumab- Tri-center 12-Month Treat-and-Extend Study. (Pubmed Central) - May 21, 2021
Moreover, the presence of ERM should not preclude DME patients from receiving anti-VEGF therapy. Future studies with larger cohorts are warranted.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. (Pubmed Central) - May 20, 2021
Future studies with larger cohorts are warranted. Eyes with nAMD receiving intravitreal anti-VEGF that were LTFU experience significant VA decline at the return visit that persists on final follow-up despite normalization of CFT.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? (Pubmed Central) - May 20, 2021
P3
This suggests that macular hemorrhages without OCT-detectable macular fluid may not require treatment and DFE may not be needed at every visit. These conclusions should be confirmed in a prospective randomized trial before firm recommendations regarding clinical practice can be made.
- || OPT-302 / Opthea, Lucentis (ranibizumab) / Roche, Novartis
P1 data, Journal: Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration. (Pubmed Central) - May 20, 2021
These conclusions should be confirmed in a prospective randomized trial before firm recommendations regarding clinical practice can be made. Intravitreal OPT-302 inhibition of VEGF-C and -D was well tolerated, and OPT-302 combination therapy may overcome an escape mechanism to VEGF-A suppression in the management of nAMD.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Optimization and method validation for the quantitative analysis of a monoclonal antibody and its related fab fragment in human plasma after intravitreal administration, using LC-MS/MS. (Pubmed Central) - May 20, 2021
Once the method was fully optimized, it was then validated, following the 2018 FDA guidance on bioanalytical method validations. This method is now available for use during clinical trials and precision medicine, for the quantitative evaluation of systemic exposure of ranibizumab or bevacizumab in human plasma after intravitreal administration, with a linear calibration range of 0.300-100 ng/mL.
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema. (Pubmed Central) - May 20, 2021
P=N/A
Thirty eyes were non-naïve and received previously thermal laser (44.3%), intravitreal injection of triamcinolone (26.7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%)...These results suggest that IAI may be beneficial in vitrectomized eyes with refractory DME which require frequent injections to obtain visual and anatomical improvement. http://www.clinicaltrials.gov, registration Number NCT02874859.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-world evidence: Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study. (Pubmed Central) - May 20, 2021
Ocular and non-ocular AEs were reported in 8.4% (n=31) and 10.1% (n=37) of patients, respectively. The LUMINOUS study confirms real-world effectiveness and safety of ranibizumab in Korean patients with nAMD; factors including age, baseline VA, and loading-dose were associated with VA gain at one-year post-treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal, Real-world evidence: Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience. (Pubmed Central) - May 20, 2021
Switching to DEX implant is feasible and safe for treating patients of DME refractory to intravitreal ranibizumab in real world. Further larger-scale or multicenter studies would be conducted to explore different DEX treatment strategies for DME, such as first-line or early switch therapy, for better BCVA improvement.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
One more: But not as ugly as Lucentis vs Avastin for treatment of AMD. (Twitter) - May 18, 2021
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Choriocapillary vascular density in central serous chorioretinopathy complicated by choroidal neovascularization. (Pubmed Central) - May 15, 2021
Further larger-scale or multicenter studies would be conducted to explore different DEX treatment strategies for DME, such as first-line or early switch therapy, for better BCVA improvement. OCTA revealed a choriocapillary hypoperfusion that may be responsable for the beginning of this disease and the late development of CNV.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Clinical features, management and outcomes of patients with sterile endophthalmitis associated with intravitreal injection of antivascular endothelial growth factor. (Pubmed Central) - May 15, 2021
It is crucial to differentiate both entities as a good diagnosis determines the visual prognosis. We should be aware of minimal inflammation after repeated intravitreal injections in order to establish the adequate treatment.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion. (Pubmed Central) - May 15, 2021
We should be aware of minimal inflammation after repeated intravitreal injections in order to establish the adequate treatment. To sum up, intravitreal injection of Lucentis was effective for both major and macular BRVO, and the efficacy in macular subtype group was better than that in major subtype group with the more obviously improvement and the less number of injections.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Head-to-Head: Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial. (Pubmed Central) - May 15, 2021
P4
Non-inferiority of combination therapy in comparison to standard therapy alone could be demonstrated. Patients with additional laser therapy needed fewer ranibizumab injections.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Management of optic disc granuloma in a patient of miliary tuberculosis with intravitreal ranibizumab in addition to antitubercular therapy. (Pubmed Central) - May 15, 2021
Patients with additional laser therapy needed fewer ranibizumab injections. No abstract available
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients. (Pubmed Central) - May 15, 2021
To extend the anti-VEGF loading dose from 3 to 6 injections necessitates investing €5882.77 (8 injections), €10,091.03 (14 injections) and €10,198.59 (30 injections) per additional responder patient (3-month nonresponders and 6-month responders) to aflibercept, ranibizumab and bevacizumab, respectively. For the total of patients treated, on average €7927.02 (14 injections) per additional responder patient would be needed.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration. (Pubmed Central) - May 15, 2021
For the total of patients treated, on average €7927.02 (14 injections) per additional responder patient would be needed. Oral cFXST increases the efficacy of short-term ranibizumab treatment for exudative AMD.
- || Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Clinical, Journal: Angiogenin, FGF-α, and IL-36β have higher expression levels in aqueous humor of nAMD patients in comparison to cataract patients. (Pubmed Central) - May 15, 2021
Angiogenin, IL-36β, and FGF-α have higher expression levels in nAMD patients in comparison to cataract patients, both before and after 2 months of ranibizumab therapy. These cytokines may have correlations with the pathogenesis of nAMD.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Observational data, Journal: A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study. (Pubmed Central) - May 15, 2021
Treatment with ranibizumab 0.5 mg resulted in significant improvements in visual outcomes among treatment-naïve Taiwanese patients with nAMD. Early treatment and frequent dosing in the real-world setting may be the key to achieving better outcomes.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-world evidence: Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab. (Pubmed Central) - May 15, 2021
Ranibizumab is well tolerated and effective in treating macular edema secondary to RVO in real-world clinical settings. However, there is under-treatment compared to controlled clinical trials, and the gain in vision is sub-optimal with under-treatment.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography - case report. (Pubmed Central) - May 15, 2021
While the type 2 lesion of the CNV reacted swiftly to the ranibizumab therapy, the type 1 lesion continued to grow. As with some other cases of ranibizumab resistance, switching to aflibercept proved effective.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study. (Pubmed Central) - May 15, 2021
Significant improvement was seen in patient visual function, and this was correlated with changes in VA, except immediately after loading dose treatment in patients with higher baseline VA. The patients' satisfaction with the treatment remained unchanged during the study period.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials. (Pubmed Central) - May 15, 2021
The administration of topical NSAIDs could achieve additional efficacy in CRT reduction and visual improvement. Both interventions had acceptable risks of adverse events.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Observational data, Retrospective data, Journal: Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration. (Pubmed Central) - May 15, 2021
P=N/A
Both interventions had acceptable risks of adverse events. Switching ranibizumab-refractory patients with nAMD to IVT-AFL may improve visual outcomes in some patients, particularly those who receive three initial monthly injections.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient. (Pubmed Central) - May 15, 2021
Switching ranibizumab-refractory patients with nAMD to IVT-AFL may improve visual outcomes in some patients, particularly those who receive three initial monthly injections. Intravitreal ranibizumab injection temporarily improved the anatomy of the eyes in a case with tamoxifen-induced CME, and only tamoxifen withdrawal can bring a sustained effect.
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial completion date, Trial termination: Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE) (clinicaltrials.gov) - May 14, 2021
P=N/A, N=47, Terminated, Sponsor: Johns Hopkins University
N=115 --> 47 | Trial completion date: Dec 2021 --> Mar 2021 | Active, not recruiting --> Terminated; The study was terminated as patients could not be followed-up during the COVID pandemic. Since this was a non-intervention study, as per Johns Hopkins University policy, we had to hold off the patient visits during the pandemic.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Correlation of Intraocular Cytokine Expression with Quantitative Ultra-widefield Fluorescein Angiographic Features in the IMAGINE Retinal Vein Occlusion Study () - May 13, 2021 - Abstract #ARVO2021ARVO_3820;
VEGF and ANGPTL4 correlated with both increased ischemia and increased leakage on UWFA. Further research is needed to evaluate the possibility of using these imaging biomarkers as surrogates for cytokine expression and correlating these features with treatment response.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Factors Predicting Treatment Frequency of Ranibizumab Injections during the Second Year in Diabetic Macular Edema () - May 13, 2021 - Abstract #ARVO2021ARVO_3728;
Further research is needed to evaluate the possibility of using these imaging biomarkers as surrogates for cytokine expression and correlating these features with treatment response. CST and hyperreflective walls in foveal cystoid spaces are designated as predictors of treatment frequency of ranibizumab injections during the second year in DME.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Optical coherence tomography biomarkers as prognostic factors in diabetic macular edema treatment with ranibizumab – vitrectomized versus non-vitrectomized eyes () - May 13, 2021 - Abstract #ARVO2021ARVO_3715;
According to our results, a normalization of the macular anatomy through the disappearance of DRIL, OPLd and ONLc with ranibizumab is most likely to happen in early complete responders. The association between INLc and higher glycated hemoglobin levels reinforces the relevance of systemic metabolic control in diabetic microvascular manifestations.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Clinical Practice Patterns of Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Treatment of Patients with Diabetic Macular Edema: A Retrospective Study () - May 13, 2021 - Abstract #ARVO2021ARVO_3712;
Aflibercept has better visual outcome among all the providers. Further studies are needed to establish an algorithm to institute a “benchmark” protocol for retina physicians in managing DME.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections () - May 13, 2021 - Abstract #ARVO2021ARVO_3216;
Despite stay-at-home orders, there was no significant decrease in the overall number of aflibercept or ranibizumab injections during the COVID pandemic compared to the prior year. Although further information is needed to determine if these injections represent both new and return patients, these data suggest that in this specific population, patients still returned to their retina specialist for care despite the ongoing pandemic.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Long-term clinical impact of intravitreal anti-VEGF therapy for severe non-proliferative diabetic retinopathy (NPDR): Analyses through a discrete event simulation model () - May 13, 2021 - Abstract #ARVO2021ARVO_3189;
Treatment impact (aflibercept and ranibizumab) was estimated based on data from clinical trials (PANORAMA, RISE/RIDE) and averaged by weighted US market share... The DES model suggests that severe NPDR treatment with intravitreal anti-VEGF therapy would significantly decrease PDR progression rates over 5 years and reduce incidence of blindness over 10 years.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficacy and outcome predictors of long-term intravitreal anti-VEGF therapy in neovascular age-related macular degeneration following a strict treat-and-extend regimen. () - May 13, 2021 - Abstract #ARVO2021ARVO_3117;
Significant visual gains were sustained after 5 years of follow-up in a TER in a real-world setting. Integrity of ELM at baseline was associated with BCVA gain and anatomic disease stability at 5 years of treatment.
- faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials () - May 13, 2021 - Abstract #ARVO2021ARVO_3116;
P3
In phase 2 studies, faricimab at up to Q16W dosing intervals was associated with robust vision and anatomic improvements, comparable with ranibizumab Q4W. TENAYA and LUCERNE phase 3 trials are evaluating efficacy, safety, and extended durability up to Q16W of intravitreal faricimab in patients with nAMD.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] A multimodal deep learning (DL) model to predict visual acuity response in the CATT study () - May 13, 2021 - Abstract #ARVO2021ARVO_3057;
P3
Compared with the BL characteristics model, the multimodal model showed slightly better performance. More research is required to explore whether the predictive ability of the multimodal model can be further improved.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Repeat Ranibizumab Injections in Retinopathy of Prematurity () - May 13, 2021 - Abstract #ARVO2021ARVO_2945;
A second IVI was performed to allow further peripheral vascularization of the retina, with the added benefit of avoiding general anesthesia in critically ill infants until they are older. IVR was chosen because it has a shorter systemic half-life compared to bevacizumab, theoretically causing less side effects.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Long term visual and neurodevelopmental outcomes in ROP patients treated with laser photocoagulation versus intravitreal anti-VEGF therapy () - May 13, 2021 - Abstract #ARVO2021ARVO_2940;
Patients treated with laser therapy were more likely to be amblyopic and were more myopic than those treated with an anti- VEGF agent. Further research would include an age-matched, larger sample size.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Incidence, severity and identification of risk factors of retinopathy of prematurity in our setting. () - May 13, 2021 - Abstract #ARVO2021ARVO_2933;
Use of O2 and respiratory distress have been associated RF, however only sepsis and transfusions showed significant differences in our research. According with the expectation of growth in the incidence of this pathology due mainly to the advancement of life support maneuvers employed in modern pediatrics, we must continue to apply these screening criteria in our center, because it has allowed the early detection of all cases of severe ROP in our center.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Analysis of Urgent Follow Up Visits and Complications After Intravitreal Injections: A Retrospective Cohort Study () - May 13, 2021 - Abstract #ARVO2021ARVO_2625;
Intravitreal injections resulted in an incidence of 0.60% urgent unscheduled follow-up visits within 7 days of injection in this large retinal specialty practice. Blurred vision and symptoms of PVD were the most common causes of urgent visits.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] DARC as a biomarker of endothelial cell stress in retinal angiogenesis () - May 13, 2021 - Abstract #ARVO2021ARVO_2482;
This is the first time in vivo that DARC has been shown to identify phosphatidylserine in angiogenic processes, and illustrates its use as a biomarker for anti-angiogenic treatments. DARC can be therefore used in vivo to identify the earliest stages of leakage and angiogenesis in choroidal neovascularisation, diabetic eye disease and potentially any retinal disease in which pathological angiogenesis occurs.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] AAO IRIS Registry data replicates VIEW 1 and VIEW 2 clinical trial outcome data () - May 13, 2021 - Abstract #ARVO2021ARVO_2461;
The proportion of eyes losing <15 across the VIEW 1 and VIEW 2 studies was similar to our registry cohort, indicating proof-of-concept, although the mean gains in letters varied across the studies. Benchmarking real-world endpoints versus randomized controlled trials could be a valuable tool in validating the predictive ability of these endpoints as a measure of effectiveness.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Immunogenicity profile of the Port Delivery System with ranibizumab in patients with nAMD () - May 13, 2021 - Abstract #ARVO2021ARVO_2452;
P2, P3
The immunogenicity profile of PDS 100 mg/mL was comparable to that of monthly RBZ, with no apparent impact of ADAs on outcomes. These data further support the efficacy and tolerability of PDS 100 mg/mL Q24W in nAMD.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] In vitro characterization of ranibizumab release from the Port Delivery System () - May 13, 2021 - Abstract #ARVO2021ARVO_2417;
P2
Ranibizumab release from the PDS implant was demonstrated to be highly predictable and tunable based on a simple diffusion model. These findings support the median time to first refill of 15.8 months in Ladder PDS 100 mg/mL patients.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] The Port Delivery System with ranibizumab (PDS)—a new paradigm for long-acting retinal drug delivery () - May 13, 2021 - Abstract #ARVO2021ARVO_2414;
P3
The PDS is an intraocular drug delivery system that continuously and reproducibly delivers ranibizumab over a period of months while maintaining potency. Archway phase 3 trial results support the efficacy of the PDS, as PDS 100 mg/mL Q24W had equivalent vision outcomes to ranibizumab Q4W averaged over weeks 36/40.
- Luminate (risuteganib) / Allegro Ophthalmics, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Suppression of Murine Choroidal and Retinal Neovascularization by Risuteganib and the Accompanying Transcriptome Changes in the OIR Retina () - May 13, 2021 - Abstract #ARVO2021ARVO_2411;
RSG demonstrated anti-NV property, reduced retinal vascular leakage, and inhibited cell adhesion and migration. Transcriptome data suggest important pathological cellular responses are modulated by RSG, with possible therapeutic implication for treatment of human retinal diseases.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Predominantely hemorragic lesion in nAMD and response to Anti-VEGF treatment () - May 13, 2021 - Abstract #ARVO2021ARVO_2337;
No difference in the result between drugs was noticed. 70% of the eyes treated showed improvement in the visual acuity.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Identification of choroidal neovascularization activity using deep learning () - May 13, 2021 - Abstract #ARVO2021ARVO_2166;
P3
Our study demonstrated that a prototype DL model can accurately detect CNV disease activity based on changes in the retinal anatomy on OCT. While this algorithm needs to be validated on other datasets, it could potentially be applied for remote and automated monitoring of nAMD.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Interpretable, feature-based predictive modeling of low and high treatment requirements in nAMD using SD- OCT () - May 13, 2021 - Abstract #ARVO2021ARVO_2165;
P3
This exploratory study showed the feasibility of identifying low or high treatment needs for patients with nAMD using predefined imaging features from automated fluid and layer SD-OCT segmentations. Further confirmation of model performance will contribute to future development of personalized healthcare algorithms.